Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenido archivado el 2024-06-18

A Novel Nano-container drug carrier for targeted treatment of prostate cancer

Objetivo

The essence of the proposal is the fabrication of multiple nano containers which exhibit double and triple stimuli response and site recognition. Specifically, the containers will be grafted by Leuprolide (LP) for prostate cancer recognition. Multiple containers will be filled by two drugs (e.g. LP and DOX) in different compartments not interacting with each other chemically (cocktail of drugs, e.g. Container1 Leuprolide (LP) and Container2 Doxorubicin (DOX)). The release can be excited by internal or external stimuli response. The internal stimuli response of our nanocontainers will require simultaneous recognition of pH, redox and/or T of the tumour. The external induction will be caused by RF excitation (hyperthermia). The nanocontainers will identify the tumour first by the agonist (LP). After trapping the container at the tumour, they will be activated by the double and triple internal excitation. This way, we achieve extremely local chemotherapy of the diseased site and the healthy organs will be untouched. Our smart nanocontainers will be tuned for prostate cancer, but our system will be evaluated for other cases such as breast cancer and thrombosis. The containers will be modified (phase transition, volume change, degradation, etc.) and deliver the drug only and if only the two sensors give positive response. The containers can be excited by external induction (Radio Frequency (hyperthermia) RF or laser light). This revolutionary strategy is necessary because the externally induced delivery methods have the disadvantage that the radiofrequency fields, the magnetic fields and the laser lights are not local but they extend over large space, larger than the size of the tumour. One cannot focus from outside the laser beam directly to the tumour only may be due to lack of imaging facilities. Our technology will prevent the release of drugs in sites where the local values correspond to the healthy tissue.

Palabras clave

Convocatoria de propuestas

ERC-2008-AdG
Consulte otros proyectos de esta convocatoria

Régimen de financiación

ERC-AG - ERC Advanced Grant

Institución de acogida

"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""
Aportación de la UE
€ 2 000 000,00
Dirección
END OF PATRIARCHOU GRIGORIOU E AND 27 NEAPOLEOS STREET
15341 Agia Paraskevi
Grecia

Ver en el mapa

Región
Αττική Aττική Βόρειος Τομέας Αθηνών
Tipo de actividad
Research Organisations
Investigador principal
George Kordas (Prof.)
Contacto administrativo
Euripides Papadopoulos (Mr.)
Enlaces
Coste total
Sin datos

Beneficiarios (1)